EMEA grants orphan drug designation for pixantrone in Europe

[News]

Cell Therapeutics, Inc. ("CTI") announced today that the European Medicines Agency (EMEA) has granted pixantrone orphan drug designation for the treatment of DLBCL which accounts for about 80% of aggressive non-Hodgkin's lymphoma.

More... (http://www.news-medical.net/news/20091221/EMEA-grants-orphan-drug-designation-for-pixantrone-in-Europe.aspx)